Release Notes for 2026-10-05: Number of new affinity data: 7831 Number of compounds (ligands) new to BindingDB: 5212 Number of Targets new to BindingDB: 7 ChEMBL release: ChEMBL 37 New Targets: Alpha-1-antitrypsin/Neutrophil elastase (unmapped): 152 inhibitors Dynamin-1-like protein [1-699] and Mitochondrial dynamics protein MID49 [126-454] (unmapped): 54 inhibitors E3 ubiquitin-protein ligase CBL-B [36-427] (Q13191): 295 inhibitors E3 ubiquitin-protein ligase CBL-C [46-435] (Q9ULV8[46-435]): 295 inhibitors Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (Q9HC29): 190 inhibitors Ribosomal protein S6 kinase alpha-2 (RSK3) (Q15349): 12 inhibitors Thyrotropin-releasing hormone-degrading ectoenzyme (Q9UKU6): 442 inhibitors Number of new Entries: 33 PubMed id or Patent id Title US12612408B2 Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof US12617759B2 Modifier of four-membered ring derivative, preparation method and application thereof US12617770B2 IRAK inhibitor and preparation method therefor and use thereof US12617772B2 Hydroxypyridine HSD17B13 inhibitors and uses thereof US12617784B2 AKT inhibitor US12617785B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss US12624018B1 Inhibitors of RIPK2 and medical uses thereof US12624022B2 Heterocyclic immunomodulators as PDL1 checkpoint inhibitor US12624028B2 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) US12624050B2 Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof US20260116867A1 PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 US20260116881A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE US20260116884A1 PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF US20260116887A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY US20260116889A1 MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT US20260124192A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS US20260124222A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY US20260125365A1 TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME US20260125370A1 SULFOXIMINE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME US20260125372A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF US20260125375A1 SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS US20260125379A1 PRODRUG OF JAK KINASE INHIBITOR US20260125380A1 PRMT5 INHIBITORS AND METHODS OF USE US20260125383A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF US20260125384A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF US20260125391A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS US20260125399A1 Substituted Pyrazolo[3,4-b]pyridine Compounds and Methods of Use Thereof US20260132122A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS US20260132127A1 NOVEL SPIRO COMPOUND US20260132132A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS US20260132136A1 Pyrazolo[5,1-f][1,2,4]triazin-4-ones as inhibitors of NOX4 US20260132140A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS US20260132158A1 PHENYL OXY AMIDE KINASE INHIBITORS